Work

MPN-091 Indirect Treatment Comparison of Momelotinib vs Fedratinib Safety in Patients With Myelofibrosis

Year: 2023

Type: conference-abstract

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/s2152-2650(23)01215-6

Authors: Lucia Masarova, Francesca Palandri, Srdan Verstovsek, Ruben Mesa, Claire Harrison, Gautam Sajeev, Boris Gorsh, Ryan Simpson, Sang Cho, Zhaohui Wang, Catherine Ellis, Sean Conlon, James Signorovitch

Institutions: The University of Texas MD Anderson Cancer Center, IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola, Wake Forest University Health Sciences, Wake Forest University, Guy's and St Thomas' NHS Foundation Trust, Analysis Group (United States), GlaxoSmithKline (United States)

Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Genetics (clinical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4386277975

Cites:

Cited by:

Related to: 10